Objectives. An experimental
Introduction: Shortening of the affected limb has frequently been observed in children with Legg-Calvé-Perthes disease (LCPD). Many factors have been thought as the cause of this residual shortening after LCPD. There has been no clear answer regarding which is more responsible for the residual shortening between coxa plana and the disturbed physeal growth. To clarify the main cause of residual shortening, clinical and experimental studies were conducted. Materials and Methods: For clinical study, 40 LCPD children with definite shortening were evaluated. This included 20 children with active disease and 20 children at skeletal maturity. Teleoroentgenograms were obtained for all children. For the experimental study, LCPD simulation in 30 piglets was achieved by disrupting the blood supply to the capital femoral epiphysis. Results: In the clinical study, total shortening in the skeletal maturity group was 14.6 mm, which consisted of 3.2 mm (16%) shortening by decreased epiphyseal height and 11.5 mm (84%) shortening by physeal growth disturbance. Total shortening in the active disease group was 7.9 mm, which consisted of 6.4 mm (84%) decrease of epiphyseal height and 1.5 mm (16%) shortening by physeal growth disturbance. In the experimental study, overall shortening (13.6 mm) in the
We wanted to evaluate the effects of a bone anabolic agent (bone morphogenetic protein 2 (BMP-2)) on an anti-catabolic background (systemic or local zoledronate) on fixation of allografted revision implants. An established allografted revision protocol was implemented bilaterally into the stifle joints of 24 canines. At revision surgery, each animal received one BMP-2 (5 µg) functionalized implant, and one raw implant. One group (12 animals) received bone graft impregnated with zoledronate (0.005 mg/ml) before impaction. The other group (12 animals) received untreated bone graft and systemic zoledronate (0.1 mg/kg) ten and 20 days after revision surgery. Animals were observed for an additional four weeks before euthanasia.Aims
Methods